Evidence map›Paper›PMID 41735928›Full record

ArticleBMC infectious diseases2026

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.

Liang Fu, Huaifang Shi, Feng Sun, Wenfei Wang, Peize Zhang, Qianting Yang, Yi Cai, Xilin Zhang, Hancheng Liang, Zhaoqing Wang and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Liang Fu *Pulmonary Diseases Department, Shenzhen Third People's Hospital, Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, Shenzhen, 518112, China.
Huaifang Shi *Health Science Center, Shenzhen University, Shenzhen, 518060, China.
Feng SunDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Wenfei WangPulmonary Diseases Department, Shenzhen Third People's Hospital, Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, Shenzhen, 518112, China.
Peize ZhangPulmonary Diseases Department, Shenzhen Third People's Hospital, Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, Shenzhen, 518112, China.
Qianting YangPulmonary Diseases Department, Shenzhen Third People's Hospital, Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, Shenzhen, 518112, China.
Yi CaiDepartment of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, Shenzhen, 518060, China.
Xilin ZhangTuberculosis Prevention and Control Department, The Fourth People's Hospital of Foshan, Foshan, 528000, China.
Hancheng LiangDivision Two of Tuberculosis Diseases Department, The Sixth People's Hospital of Dongguan, Dongguan, 523000, China.
Zhaoqing WangPulmonary Diseases Department, Shenzhen Third People's Hospital, Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, Shenzhen, 518112, China.
Juan XiongHealth Science Center, Shenzhen University, Shenzhen, 518060, China.
Xinchun ChenDepartment of Pathogen Biology, Guangdong Key Laboratory of Regional Immunity and Diseases, Shenzhen University School of Medicine, Shenzhen, 518060, China. chenxinchun@szu.edu.cn.
Wenhong ZhangDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, 200040, China. zhangwenhong@fudan.edu.cn.
Guofang DengPulmonary Diseases Department, Shenzhen Third People's Hospital, Guangdong Provincial Clinical Research Center for Infectious Diseases (Tuberculosis), Shenzhen Clinical Research Center for Tuberculosis, National Clinical Research Center for Infectious Disease (Shenzhen), Southern University of Science and Technology, Shenzhen, 518112, China. jxxk1035@yeah.net.

Funding

National Key Research and Development Program of China 2023YFC2307200Science, Technology and Innovation Commission of Shenzhen Municipality KCXFZ20211020163811027
6 · The paper itself

Abstract

backgroundRifampicin-resistant tuberculosis (RR-TB) remains a major public health threat. Nine-month, all-oral regimens containing bedaquiline (Bdq) and linezolid (Lzd) have shown high cure rates, but evidence on the durability of results beyond 24 months and long-term linezolid-induced neurotoxicity is limited.

methodsWe conducted a multicentre, prospective cohort study (MDR-Chin) involving 124 adults with culture-confirmed MDR/RR-TB or pre-extensively drug-resistant tuberculosis (pre-XDR-TB) enrolled between May 2020 and July 2022. Patients received one of four nine-month, all-oral regimens containing Lzd (600 mg/day). We assessed outcomes 36 months after treatment completion. The primary efficacy outcome was a favourable outcome (absence of failure, relapse, or death). The safety outcome was persistent, clinician-confirmed Lzd-related neuropathic/visual symptoms present for at least 24 months.

resultsAt 36 months after treatment completion, 111 of 124 participants (89.5%, 95% CI 82.9–93.8) achieved a favourable outcome. No significant differences in favourable outcomes were observed between the four regimens (log-rank p > 0.05). Overall, 28 out of 124 patients (22.6%) reported at least one persistent linezolid-related neuropathic or visual symptom. The most frequent symptom was foot numbness (22/124; 17.7%).

conclusionIn this non-randomised multicentre cohort, nine-month all-oral therapy for RR-TB demonstrated durable three-year outcomes. However, linezolid-related persistent neuropathy remained common and warrants proactive mitigation, including optimisation to reduce cumulative linezolid exposure or adoption of linezolid-sparing alternatives when feasible.

Indexed as

Antitubercular AgentsLinezolidRifampinTuberculosis, Multidrug-ResistantAdministration, OralAdultChinaDiarylquinolinesFemaleHumansMaleMiddle AgedProspective StudiesTreatment OutcomeAntitubercular AgentsbedaquilineDiarylquinolinesLinezolidRifampincohort studyLinezolidLong-term outcomeneuropathyNine-monthRifampicin-resistant tuberculosis

Identifiers

PMID41735928
PMCPMC13041266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.